2026-05-15T15:54:04+00:00 2025-06-30 990 2024-07-01 730580274 Oklahoma Medical Research Foundation OKLA 4052717421 825 NE 13th Street Oklahoma City OK 73104 Tim Hassen VP and Chief Financial Officer 4052717421 2026-05-15 2024 2025-03-06 01:10:19Z Tim Hassen VP and CFO 825 NE 13th Street Oklahoma City OK 73104 267452700 false X www.omrf.org X 1946 OK Oklahoma Medical Research Foundation (OMRF) is dedicated to developing a better understanding of and more effective treatments for human disease. 62 62 659 62 89 0 88644965 86153223 29301960 32877905 7458610 8998064 6926766 8747637 132332301 136776829 0 0 51893083 55922704 0 3230304 67811404 70554283 119704487 126476987 12627814 10299842 528771950 560513987 39302223 34404489 489469727 526109498 X OMRF is dedicated to developing a better understanding of more effective treatments for human disease. false false 47419059 23793202 Arthritis and Clinical Immunology/Clinical Operations - OMRF continued to build on its national leadership in autoimmune disease research and care. In 2025, physicians in the foundation's clinics treated more than 3,000 patients living with conditions such as lupus, multiple sclerosis and rheumatoid arthritis. At the same time, OMRF expanded its portfolio of clinical trials, serving as a leading site for some of the first U.S. studies designed to prevent autoimmune diseases before symptoms appear. These trials focus on people at high risk of developing lupus or rheumatoid arthritis and aim to better understand how these illnesses begin - and how they might be delayed or stopped. 11214388 13077342 Aging and Metabolism Research Program - OMRF's Aging & Metabolism Research Program continued to advance research into how aging affects the body and how those changes might be slowed. The program welcomed a new investigator, Dr. David Hughes, whose work explores how cells recycle proteins to maintain healthy tissues. Program scientists also earned national recognition, with Dr. Sue Bodine named president-elect of the American Physiological Society and Dr. Benjamin Miller completing his term as president of the American Aging Association. Researchers secured new federal grants and training awards, performed public outreach on healthy aging and neurodegenerative disease, and launched a first-of-its-kind clinical trial examining why some older adults respond better to certain forms of exercise than others. 9664447 10827654 Cardiovascular Biology Research Program - Scientists in OMRF's Cardiovascular Biology Research Program made discoveries that could reshape understanding of diseases affecting blood vessels and circulation. Dr. Courtney Griffin revealed new ways blood vessels can be damaged during conditions such as Tylenol overdose and diabetes-related eye disease, and she identified a potential strategy to protect delicate eye capillaries and preserve vision in early stages of disease. Meanwhile, Dr. Sathish Srinivasan discovered that malfunction of the body's lymphatic vessels may contribute to Crohn's disease, pointing to a possible new avenue for treatment. 48805337 38720279 Other program services include departments such as Cell Cycle and Cancer Biology, Genes and Human Disease, Center for Biomedical Data Sciences and other scientific and research support services. 48805337 38720279 117103231 true true false true false false false false false true true true false true true true true true false false true false false false true false false false false true true false false false false false false false false false false true false false false true false false false false false true 216 0 true 659 true true true false false false true true true true false false false true true false false false X 62 62 false false false false false false false true true false false false true true true true true true true true false false OK X X Tim Hassen VP and Chief Financial Officer 4052717421 825 NE 13th Street Oklahoma City OK 73104 Ann Felton Board Member 1.0 X 0 0 0 Barbara Braught Board Member 1.0 X 0 0 0 Barry Pollard MD Board Member 1.0 X 0 0 0 Becky Switzer Board Member 1.0 X 0 0 0 Betsy Thorpe Board Member 1.0 X 0 0 0 Bill Anoatubby Board Member 1.0 X 0 0 0 Bill Hawley MD Board Member 1.0 X 0 0 0 Brett Jameson MD Board Member 1.0 X 0 0 0 Brooks Hall Board Member 1.0 X 0 0 0 Bruce Benbrook Board Member 1.0 X 0 0 0 Burns Hargis Board Member 1.0 X 0 0 0 Christy Everest Board Member 1.0 X 0 0 0 Claire Eagan Board Member 1.0 X 0 0 0 Cliff Hudson Board Member 1.0 X 0 0 0 Dan Little Board Member 1.0 X 0 0 0 David Rainbolt Board Member 1.0 X 0 0 0 Dee Replogle Board Member 1.0 X 0 0 0 Ellen Burgess Board Member 1.0 X 0 0 0 Gail Muncrief Board Member 1.0 X 0 0 0 Gerald Gamble Board Member 1.0 X 0 0 0 Greg Walton MD Board Member 1.0 X 0 0 0 Harrison Levy Board Member 1.0 X 0 0 0 Hiram Champlin Board Member 1.0 X 0 0 0 Jack McCarty Board Member 1.0 X 0 0 0 Jack Stark Board Member 1.0 X 0 0 0 Jacqui Haglund Board Member 1.0 X 0 0 0 Jerome Holmes Board Member 1.0 X 0 0 0 JII Boghetich Board Member 1.0 X 0 0 0 Jim Morris Board Member 1.0 X 0 0 0 John Griffin Board Member 1.0 X 0 0 0 John Saxon III MD Board Member 1.0 X 0 0 0 Judy Hatfield Board Member 1.0 X 0 0 0 Karin Holsted Board Member 1.0 X 0 0 0 Kimbra Scott Board Member 1.0 X 0 0 0 Lance Benham Board Member 1.0 X 0 0 0 Larry Nichols Board Member 1.0 X 0 0 0 Leigh Ann Albers Board Member 1.0 X 0 0 0 Len Cason Board Member 1.0 X 0 0 0 Lisa Dillingham Board Member 1.0 X 0 0 0 Mark Funke Board Member 1.0 X 0 0 0 Martin Bautista MD Board Member 1.0 X 0 0 0 Mautra Jones EdD Board Member 1.0 X 0 0 0 Meg Salyer Board Member 1.0 X 0 0 0 Michael Cawley Board Member 1.0 X 0 0 0 Mindy Mahaney Board Member 1.0 X 0 0 0 Pat Rooney Board Member 1.0 X 0 0 0 Paul Schulte Board Member 1.0 X 0 0 0 Rainey Williams Jr Board Member 1.0 X 0 0 0 Ramsey Drake Board Member 1.0 X 0 0 0 Randy Brown MD Board Member 1.0 X 0 0 0 Randy Hogan Board Member 1.0 X 0 0 0 Rebecca Patten Board Member 1.0 X 0 0 0 Richard Parry Board Member 1.0 X 0 0 0 Ronnie Irani Board Member 1.0 X 0 0 0 Sarah Yauk Board Member 1.0 X 0 0 0 Sharon Bell Board Member 1.0 X 0 0 0 Sherri Lance Board Member 1.0 X 0 0 0 Steven Taylor Board Member 1.0 X 0 0 0 Terence Kern Board Member 1.0 X 0 0 0 Tricia Everest Board Member 1.0 X 0 0 0 Virginia Groendyke Board Member 1.0 X 0 0 0 Walt Duncan IV Board Member 1.0 X 0 0 0 Adam Cohen SVP and General Counsel 50.0 X 326153 0 68468 Andrew Weyrich PhD President and CEO 50.0 X 818633 0 50763 Courtney Greenwood VP of Human Resources 50.0 X 207544 0 38327 Courtney Griffin PhD VP of Research 50.0 X 307420 0 63830 Judith James EVP and Chief Medical Officer 50.0 X 876648 0 139926 Lisa Day VP of Government Relations and Advocacy 50.0 X 210081 0 43533 Penny Voss VP of Philanthropy and Community Relations 50.0 X 270186 0 60801 Tim Hassen VP and Chief Financial Officer 50.0 X 291289 0 74490 Benjamin Miller PhD Program Chair, Aging and Metabolism 50.0 X 175939 0 20325 Gabriel Pardo MD Professor Clinical Neurology, Arthritis and Clinical Immunology 50.0 X 410861 0 53100 Lijun Xia PhD Program Chair, Cardiovascular Biology 50.0 X 304307 0 64952 Patrick Gaffney MD Program Chair, Genes and Human Disease 50.0 X 277651 0 55744 Chelsea Berkley MD Clinical Assistant Professor, Arthritis and Clinical Immunology 50.0 X 250814 0 30558 Florea Lupu PhD Professor, Cardiovascular Biology 50.0 X 342973 0 40999 Joel Guthridge PhD Associate Professor, Arthritis and Clinical Immunology 50.0 X 252039 0 31301 Swapan Nath PhD Professor, Arthritis and Clinical Immunology 50.0 X 308762 0 43590 Yang Mao-Draayer PhD Professor Clinical Neurology, Arthritis and Clinical Immunology 50.0 X 290487 0 32892 5921787 0 913599 90 false true false Infusion Management LLC 11233 Shadow Creek Pwky Suite 303 Pearland TX 77584 Infusion Management Services 24643904 Aramark 24863 Network Pl Chicago IL 606731248 HouseKeeping Services 682547 Miles Architecture LLC 865 Research Pkwy Suite 100 Oklahoma City OK 73104 Architectural services 502682 Beck Associates Architects PLLC 110 W 7th St Ste 710 Tulsa OK 74119 Architectural Services 233590 CapTrust Partners LLC 4208 Six Forks Rd Ste 1700 Raleigh NC 27609 Investment Management Services 150961 5 88481 1146963 53057578 31860201 476585 86153223 Clinic Revenue 621990 32877905 32877905 0 0 0 0 32877905 12047510 447 12047063 146231 146231 5295608 3182242 2113366 467781 467781 0 467781 467781 127219512 20871 130417433 18627 -3197921 2244 -3195677 -358 -3195319 69600 1146963 239811 -170211 -170211 Laboratory Income 621500 2660133 2660133 Cafe Income 722514 494326 494326 0 0 0 0 3154459 136776829 38720280 89 11903237 4476713 3720498 486029 270186 38100870 35162949 1595136 1342785 3223980 2944260 157586 122134 7231058 6304721 706747 219590 2890083 2639333 141265 109485 196099 144683 51416 161163 161163 83574 83574 3477172 3477172 0 0 844307 392323 75696 376288 2324172 1763854 349226 211092 5879636 4802835 1076684 117 921416 856868 44581 19967 276762 240479 393 35890 181426 175904 5522 8633668 8300484 333184 680401 502004 178397 Subcontracts 31853325 31853325 Lab supplies 8871167 8871167 Other 3482784 2287627 682755 512402 Inhouse 1896752 1872285 14099 10368 790459 790459 0 0 126476987 117103230 6143453 3230304 3640 2400 44170006 45812921 14620131 16092286 9054128 8899916 0 0 0 0 79411 91578 1174683 898990 1008212 768084 255778407 167541156 85631955 88237251 177316130 192830394 32687772 36177302 0 163025882 170702865 528771950 560513987 18280141 16954218 2838255 1833419 7875000 4765000 0 0 10308827 10851852 39302223 34404489 195929685 206601526 293540042 319507972 489469727 526109498 528771950 560513987 X 10299842 18841615 7498314 X false true true true true X 91435276 70293950 71342417 88644965 86153223 407869831 0 0 91435276 70293950 71342417 88644965 86153223 407869831 71220252 336649579 8109982 15219254 11853866 31741457 14774441 81699000 10725 51456 0 0 0 62181 158503 260020 425851 526475 563926 1934775 491565787 167488741 0.68485 0.68282 X Schedule A, Part II, Line 10 Schedule A, Part II, Line 10 Other income includes cafeteria sales as well as fundraising income that was not included in contributions. Schedule A, Part II, Line 10 Other Income DESCRIPTION - , COLUMN A - 158503.0, COLUMN B - 260020.0, COLUMN C - 425851.0, COLUMN D - 526475.0, COLUMN E - 563926.0, COLUMN F - 1934775.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 491506 false false 491506 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY The Foundation's lobbying activities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 197304412 630484 24937288 8300000 214572184 177673255 1162889 25868268 7400000 197304412 158042345 7689037 17641873 5700000 177673255 169632776 12453227 -18843658 5200000 158042345 116281093 18987421 39164262 0 4800000 0 169632776 0.3423 0.308 0.3497 true false 4080847 4080847 193623830 133140968 60482862 53745331 33892034 19853297 4328399 508154 3820245 88237251 Closely-held equity interests Financial derivatives Other securites 36177302 F 36177302 Funds held in trust by others 158811072 Wills and Bequests 2168231 Cash Surrender Value of Life Insurance 8704924 Debt Issue Costs 26617 Deposits 708813 Accrued Interest Receivable 217568 Assets Held for Sale 65520 Minerals 120 170702865 Federal Income Taxes Postretirement Benefits and Deferred Comp 10450880 Split Interest Agreements 76488 Long-term Lease Liability 324484 10851852 X 163116758 18841615 7498314 26339929 136776829 0 0 136776829 126476987 0 0 126476987 0 0 126476987 Schedule D, Part XI, Line 2(d) Includes change in fair value of funds held in trust by others of $7,618,096 as well as pension related changes other than net periodic pension costs of $(119,782). Schedule D, Part V, Line 4 Intended uses of endowment funds The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote The Foundation is a public foundation exempt from federal income tax under section 501(c)(3) of the internal revenue code except for amounts relating to unrelated business income. There were no known material unrelated business income taxes incurred in 2025 and accordingly, no provision for income taxes has been made in these financial statements. Management has reviewed the Foundation's tax position and concluded that there are no uncertain tax positions that require accrual in the consolidated financial statements or disclosure in the footnotes to be in compliance with authoritative literature. Generally, the Foundation is no longer subject to income tax examination by federal, state or local tax authorities for years prior to 2022. The statute of limitations will remain open for both federal and state purposes for any returns not filed. Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 CHANGES IN FAIR VALUE OF FUNDS HELD IN TRUST - 7618096 PENSION RELATED CHANGES OTHER THAN NET PERIODIC PENSION COSTS - -119782 Europe (Including Iceland and Greenland) 0 31 Conference Travel 68172 Europe (Including Iceland and Greenland) 0 9 Program Services Student Program 12846 North America (Canada & Mexico only) 0 14 Conference Travel 26900 South Asia 0 1 Conference Travel 3104 South America 0 2 Conference Travel 5610 East Asia and the Pacific 0 4 Conference Travel 15155 North America (Canada & Mexico only) 0 0 Investments 2255762 Central America and the Caribbean 0 0 Investments 15988158 0 61 0 0 0 61 18375707 0 18375707 true false false true true false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements CENTRAL AMERICA AND THE CARIBBEAN-Accrual; EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual Schedule F, Part V Program service activity in all regions includes scientists attending and/or speaking at scientific conferences and collaborations. OMRF does not maintain ongoing operations in foreign jurisdictions, however the Foundation's scientists do travel to various scientific conferences in other countries to share in scientific discoveries, as well as to learn from other scientists across the world. 241 EVENT 688563 634563 54000 30400 20282 87850 60523 MS DINNER 528000 512400 15600 1500 18660 11295 9301 0 1216563 1146963 69600 31900 38942 99145 69824 239811 -170211 X X X true true X X X X X false true false false false false false true false Andrew Weyrich PhD President and CEO 595766 0 168000 0 54867 0 37655 0 13108 0 869396 0 0 0 Judith James EVP and Chief Medical Officer 457533 0 10225 0 408890 0 132012 0 7914 0 1016574 0 357135 0 Adam Cohen SVP and General Counsel 273111 0 275 0 52767 0 60762 0 7706 0 394621 0 0 0 Tim Hassen VP and Chief Financial Officer 270262 0 450 0 20577 0 57879 0 16611 0 365779 0 0 0 Courtney Greenwood VP of Human Resources 202964 0 150 0 4430 0 30621 0 7706 0 245871 0 0 0 Courtney Griffin PhD VP of Research 296845 0 125 0 10450 0 48594 0 15236 0 371250 0 0 0 Lisa Day VP of Government Relations and Advocacy 206964 0 0 0 3117 0 35827 0 7706 0 253614 0 0 0 Penny Voss VP of Philanthropy and Community Relations 230192 0 0 0 39994 0 51079 0 9722 0 330987 0 0 0 Benjamin Miller PhD Program Chair, Aging and Metabolism 174684 0 75 0 1180 0 14868 0 5457 0 196264 0 0 0 Gabriel Pardo MD Professor Clinical Neurology, Arthritis and Clinical Immunology 408844 0 0 0 2017 0 37864 0 15236 0 463961 0 0 0 Lijun Xia PhD Program Chair, Cardiovascular Biology 263493 0 0 0 40814 0 59683 0 5269 0 369259 0 0 0 Patrick Gaffney MD Program Chair, Genes and Human Disease 264384 0 0 0 13267 0 40508 0 15236 0 333395 0 0 0 Chelsea Berkley MD Clinical Assistant Professor, Arthritis and Clinical Immunology 250227 0 0 0 587 0 25289 0 5269 0 281372 0 0 0 Florea Lupu PhD Professor, Cardiovascular Biology 319973 0 0 0 23000 0 36219 0 4780 0 383972 0 0 0 Yang Mao-Draayer PhD Professor Clinical Neurology, Arthritis and Clinical Immunology 252235 0 0 0 38252 0 23467 0 9425 0 323379 0 0 0 Joel Guthridge PhD Associate Professor, Arthritis and Clinical Immunology 224539 0 0 0 27500 0 26032 0 5269 0 283340 0 0 0 Swapan Nath PhD Professor, Arthritis and Clinical Immunology 271725 0 0 0 37037 0 33938 0 9652 0 352352 0 0 0 Schedule J, Part I, Line 1a First-class or charter travel First class travel is allowed for the CEO to allow him to accomplish work related to tasks while traveling. Schedule J, Part I, Line 1a Travel for companions Travel for companions is allowed in certain limited circumstances where the companion's presence has a benefit to the Foundation but does not qualify as a business expense under IRS rules. In those limited cases the companion's travel expenses are treated as taxable compensation. Schedule J, Part I, Line 1a Tax indemnification and gross-up payments The Foundation's policy is to provide gross-up payments for all employee relocation expenses. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan The Board of the Foundation periodically uses non-qualified retirement plans as a retention tool. The amount reported is the amount vested in the 457(f) plan. The remaining amount of the plan is not vested and is subject to substantial risk of forfeiture. Schedule J, Part I, Line 7 Non-fixed payments The President receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comparability data from widely accepted peer benchmarking surveys that are segmented by region and size of entity. A Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2016 736194355 000000000 2016-07-13 29535000 Refunding of prior year 2008 bond false false false A 24770000 0 29535000 2953564 0 26315325 266175 0 0 0 0 0 2016 false true true true A false false false false true true 0.0044 0.0 0.0044 false false 0 false true A false false false true false false 0 false false false 0 false false true A true Schedule K, Part I 07/13/2016 29535000 Oklahoma Industries Authority In July 2016, the Foundation entered into advanced refinancing of the Series 2008 bonds. The Foundation issued $43,955,000 of OIA Series 2008 Revenue Bonds (the "Series 2008 Bonds") dated July 1, 2008; the proceeds from this bond were used to construct and equip a new research facility. The Series 2008 Bonds were defeased when the Foundation issued $29,535,000 of OIA Series 2016 Revenue Bonds (the "Series 2016 Bonds") dated July 13, 2016. The Series 2016 Bonds mature on July 1, 2026 and bear interest at the stated rate of 1.81% per annum. Payments of principal and interest began January 1, 2017 and are due January 1st and July 1st of each year. The Series 2016 Bond agreements also require maintenance of a reserve fund which is included in investments in the accompanying statement of financial position. This amount was $2,953,500 as of June 30, 2025. Schedule K, Part IV, Line 2c COLUMN A Issuer name: Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2016 The calculation for computing no rebate due was performed on 07/01/2021 18 476585 Market value 0 false true true Schedule M, Part I, Line 32b Third parties used to solicit, process, or sell noncash contributions The Foundation contracts with a service organization who solicits the donation of vehicles. The service organization is responsible for communication with the donor as well as the selling process. The Foundation receives a check for 80% of the proceeds from the sale of the vehicle. Form 990, Part III, Line 4a-4c Description of program services (Expenses $ 48,805,337 including grants of $)(Revenue $ 38,720,279) Other program services include departments such as Cell Cycle and Cancer Biology, Genes and Human Disease, Center for Biomedical Data Sciences and other scientific and research support services. Form 990, Part VI, Line 1a Delegate broad authority to a committee The Foundation's Board of Directors has delegated all of its powers to the Foundation's Executive Committee, except as follows: establish the overall policies and direction of the Foundation, appoint the members of the Executive Committee, elect and remove the Chair of the Board of Directors, amend the Bylaws and the Certificate of Incorporation of the Foundation, and appoint special committees to the Board of Directors. The Board of Directors may at any time amend or revoke this delegation of powers. Form 990, Part VI, Line 11b Review of form 990 by governing body The Form 990 is prepared by the Foundation, internally reviewed by the CFO. The Form 990-T is externally reviewed by the tax department of a public accounting firm. A summary of the Form 990 is presented for review to the Executive Committee. Subsequent to that review, the Form 990 with all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. Form 990, Part VI, Line 12c Conflict of interest policy Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest policy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officer and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a potential conflict exists and is material. If a potential material conflict is identified, the committee analyzes whether the contemplated transaction may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendation to the Foundations' Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and , where applicable, management of all such potential conflicts rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. Form 990, Part VI, Line 15a Process to establish compensation of top management official Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer bench marking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 15b Process to establish compensation of other employees Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer bench marking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 18 How forms are made available to the public The Foundation's Form 990 for the last three years are publicly available on the Foundation's website, as well as on Candid and other nonprofit databases. Form 1023, 990, and 990-T are provided upon request. Form 990, Part VI, Line 19 Required documents available to the public The Foundation's governing documents, conflict of interest policy, and financial statements are provided upon request and are publicly available on the Foundation's website. Form 990, Part XI, Line 9 Includes change in fair value of funds held in trust by others of $7,618,096 as well as pension related changes other than net periodic pension costs of $(119,782). Form 990, Part XI, Line 9 Other changes in net assets or fund balances CHANGES IN FAIR VALUE OF FUNDS HELD IN TRUST - 7618096; PENSION RELATED CHANGES OTHER THAN NET PERIODIC PENSION COSTS - -119782; Total - 7498314; Schedule F, Part I, Line 3 Program service activity in all regions includes scientists attending and/or speaking at scientific conferences and collaborations. OMRF does not maintain ongoing operations in foreign jurisdictions however the Foundation's scientists do travel to various scientific conferences in other countries to share in scientific discoveries, as well as, to learn from other scientists across the world. Form 990, Part VI Section A, Line 2 The Foundation currently has 62 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of Board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation. Culbertson Plaza LLC 825 NE 13th Street Oklahoma City OK 73104 842527142 Manage real property known as the Culbertson Plaza Shopping Center OK 211722 1373955 Oklahoma Medical Research Foundation